Inner Cosmos is a pioneering startup in the field of brain-computer interfaces (BCI), specifically designed to address cognitive disorders in humans. The company’s primary mission is to combat depression, the most widespread chronic disorder globally. Inner Cosmos has developed a groundbreaking product called the "Digital Pill," a tiny device about the size of a penny that is implanted just under the skin. This device rebalances brain networks through imperceptible micro-stimulations, without the need for invasive procedures or entering the brain itself.

The Digital Pill offers several advantages over traditional treatments like Transcranial Magnetic Stimulation (TMS), Electroconvulsive Therapy (ECT), and ketamine. Unlike these methods, which often require multiple, lengthy clinic visits, the Digital Pill is mobile and adapts to the user’s lifestyle. It provides precise, individualized treatment by focusing micro-stimulations on specific brain networks, thereby eliminating the risks associated with invasive neurosurgery.

Inner Cosmos operates in the neuromedicine market, targeting individuals suffering from depression and potentially other cognitive disorders in the future. The company’s business model revolves around the sale and implantation of the Digital Pill, as well as potential subscription services for ongoing monitoring and adjustments. Revenue is generated through the initial sale of the device, follow-up services, and possibly through partnerships with healthcare providers and insurance companies.

The leadership team includes notable figures like Meron Gribetz, a pioneer in augmented reality, and Ed Boyden, a leader in optogenetics and temporal interference. Their combined expertise positions Inner Cosmos at the forefront of a new era in psychiatric care.

Keywords: brain-computer interface, depression treatment, Digital Pill, cognitive disorders, neuromedicine, micro-stimulations, non-invasive, precision therapy, mental health, innovative healthcare.